company background image
ESPR

Esperion Therapeutics NasdaqGM:ESPR Stock Report

Last Price

US$5.51

Market Cap

US$347.2m

7D

-10.8%

1Y

-72.7%

Updated

26 May, 2022

Data

Company Financials +
ESPR fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health1/6
Dividends0/6

ESPR Stock Overview

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol.

Esperion Therapeutics Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Esperion Therapeutics
Historical stock prices
Current Share PriceUS$5.51
52 Week HighUS$26.77
52 Week LowUS$3.28
Beta0.42
1 Month Change5.56%
3 Month Change31.50%
1 Year Change-72.72%
3 Year Change-88.67%
5 Year Change-83.02%
Change since IPO-62.00%

Recent News & Updates

May 07

Esperion Therapeutics: 2021 Labors Paying Off In 2022

Esperion Therapeutics reported their Q1 earnings that revealed a beat on EPS and revenue. The company reported $13.4M in U.S. product revenue for Q1, which was up around 109% year-over-year. Esperion had a 32% year-over-year cost savings of the company operating expenses compared to the first quarter of 2021. The company believes they are "financed through the readout of the CLEAR Outcomes trial and for the foreseeable future beyond that". I believe investors should be applauding Esperion's recent success and ought to be enthusiastic about the company’s long-term potential.

Shareholder Returns

ESPRUS PharmaceuticalsUS Market
7D-10.8%1.6%1.0%
1Y-72.7%13.6%-15.1%

Return vs Industry: ESPR underperformed the US Pharmaceuticals industry which returned 13.6% over the past year.

Return vs Market: ESPR underperformed the US Market which returned -15.1% over the past year.

Price Volatility

Is ESPR's price volatile compared to industry and market?
ESPR volatility
ESPR Average Weekly Movement12.0%
Pharmaceuticals Industry Average Movement11.7%
Market Average Movement7.8%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market2.9%

Stable Share Price: ESPR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: ESPR's weekly volatility (12%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2008218Sheldon Koenighttps://www.esperion.com

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program.

Esperion Therapeutics Fundamentals Summary

How do Esperion Therapeutics's earnings and revenue compare to its market cap?
ESPR fundamental statistics
Market CapUS$347.17m
Earnings (TTM)-US$234.90m
Revenue (TTM)US$89.31m

3.9x

P/S Ratio

-1.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ESPR income statement (TTM)
RevenueUS$89.31m
Cost of RevenueUS$121.90m
Gross Profit-US$32.59m
Other ExpensesUS$202.31m
Earnings-US$234.90m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-3.73
Gross Margin-36.50%
Net Profit Margin-263.03%
Debt/Equity Ratio-211.0%

How did ESPR perform over the long term?

See historical performance and comparison

Valuation

Is Esperion Therapeutics undervalued compared to its fair value and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: ESPR ($5.51) is trading below our estimate of fair value ($69.32)

Significantly Below Fair Value: ESPR is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ESPR is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US Pharmaceuticals industry average.

PE vs Market: ESPR is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ESPR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ESPR has negative assets, so we can't compare its Price-To-Book Ratio to the US Pharmaceuticals industry average.


Future Growth

How is Esperion Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


70.9%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ESPR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: ESPR is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ESPR's is expected to become profitable in the next 3 years.

Revenue vs Market: ESPR's revenue (45.2% per year) is forecast to grow faster than the US market (8% per year).

High Growth Revenue: ESPR's revenue (45.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ESPR's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Esperion Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-13.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ESPR is currently unprofitable.

Growing Profit Margin: ESPR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ESPR is unprofitable, and losses have increased over the past 5 years at a rate of 13.6% per year.

Accelerating Growth: Unable to compare ESPR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ESPR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.9%).


Return on Equity

High ROE: ESPR's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Financial Health

How is Esperion Therapeutics's financial position?

Financial Health Score

1/6

Financial Health Score 1/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ESPR has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: ESPR has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: ESPR has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: ESPR's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ESPR has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ESPR has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Esperion Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ESPR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ESPR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ESPR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ESPR's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ESPR has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average management tenure


CEO

Sheldon Koenig (55 yo)

1

Tenure

US$7,776,226

Compensation

Mr. Sheldon L. Koenig has been President, Chief Executive Officer and Director at Esperion Therapeutics, Inc. since May 17, 2021 and had been its Chief Operating Officer since December 15, 2020 until May 1...


CEO Compensation Analysis

Compensation vs Market: Sheldon's total compensation ($USD7.78M) is above average for companies of similar size in the US market ($USD2.63M).

Compensation vs Earnings: Sheldon's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: ESPR's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

Experienced Board: ESPR's board of directors are considered experienced (3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ESPR insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 123.5%.


Top Shareholders

Company Information

Esperion Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Esperion Therapeutics, Inc.
  • Ticker: ESPR
  • Exchange: NasdaqGM
  • Founded: 2008
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$347.166m
  • Shares outstanding: 63.01m
  • Website: https://www.esperion.com

Number of Employees


Location

  • Esperion Therapeutics, Inc.
  • 3891 Ranchero Drive
  • Suite 150
  • Ann Arbor
  • Michigan
  • 48108
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/26 00:00
End of Day Share Price2022/05/26 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.